Authors
Latest:
ARVO 2025: Dr. Jogin Desai provides Phase 2 updates from a first-in-human RPE cell suspension trialThe trial will assess allogeneic retinal pigment epithelium cells in the treatment of geographic atrophy.
Latest:
ACHIEVING IMPROVED OUTCOMES THROUGH PARTNERSHIPS BETWEEN OPTOMETRISTS AND RETINA SPECIALISTSConsiderations in the treatment of diabetic retinopathy and diabetic macular edema.
Latest:
Managing neovascular retinal disease in COVID-19 era requires careful approachMinimizing clinic visits, maximizing use of imaging modalities are key.
Latest:
ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopiaOutcomes from high myopia LASIK using the Teneo laser platform demonstrate strong visual stability and patient satisfaction, with reduced dysphotopsias and minimal reliance on cycloplegia or nomograms.
Latest:
ACHIEVING IMPROVED OUTCOMES THROUGH PARTNERSHIPS BETWEEN OPTOMETRISTS AND RETINA SPECIALISTSConsiderations in the treatment of diabetic retinopathy and diabetic macular edema.
Latest:
Focusing on postinjection endophthalmitisSystemic immunosuppression may prevent devastating complication in patients.
Latest:
Seize underutilized opportunity to treat glaucoma during vitrectomyOphthalmologists can reduce IOP and medications with endocyclophotocoagulation while in the eye.
Latest:
Benefits of topography-guided treatments for irregular corneasProcedure can improve best-corrected visual acuity, enhancing quality of life for patients.
Latest:
Inherited retinal diseases meet their therapeutic matchThe retina is a key proving ground for long-held theories of genetics.
Latest:
Q&A: Deepak Sambhara, MD, discusses real-world follow-up for patients with GAA study reveals attrition rates in geographic atrophy patients on complement inhibitor therapies, highlighting the need for improved treatment compliance strategies.
Latest:
The evolving role of vitreosurgical simulators in surgical trainingNeed to eliminate errors results in optimization of training of novice surgeons.
Latest:
Considerations for the Future of Biosimilars in the Treatment of Retinal DisordersCarl D. Regillo, MD, and Jennifer I. Lim, MD, emphasize the high regulatory standards of equivalence and safety of biosimilars in considering the role they will play in the evolving treatment landscape for retinal disorders.
Latest:
Q&A: Dilraj S. Grewal, MD, FASRS, on therapeutics for non-infectious uveitisDilraj S. Grewal, MD, FASRS, provides an in-depth overview of the current state of research and treatment innovations.
Latest:
CCS 2025: Patient journey with neovascular retinal disease through advanced treatment and beyondDeep Parikh, MD, sat down with Emily Kaiser Maharjan from Optometry Times to talk about his presentation at Collaborative Care Symposium on advanced treatments in neovascular retinal disease.
Latest:
Increasing your practice’s reach, relevance, and revenue with clinical trialsWorking as an investigator can prove to be a positive experience for physicians
Latest:
Mixing and Matching Monofocal Plus IOLs with Other Advanced Technology IOLsKamran Riaz, MD, reviews a cataract surgery case where the patient was fitted with different IOLs in each eye.
Latest:
EnVision Summit 2025: Complications in glaucoma surgeryAt the EnVision Summit 2025 in San Juan, Puerto Rico, Tania Tai, Lucy Shen, and Shivani Kamat all gave insight into complications they have seen while performing glaucoma surgery.
Latest:
The eyes offer conjunctival clue to COVID-19A patient's vision loss leads to another diagnosis
Latest:
From waste to wonder: Transformational advances in scleral allograft technologyUnlocking the potential of donor scleral tissue: Innovations and future applications.
Latest:
Subretinal drusenoid deposits: Marker for unrecognized cardiac diseaseNew research reveals subretinal drusenoid deposits as potential indicators of serious heart disease, highlighting the need for ophthalmologists to screen patients effectively.
Latest:
ARVO 2025: Shortened, maintained, or extended dosing intervals through 96 weeks in PHOTONAt ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg versus 2 mg during the matched dosing phase, and outcomes of shortened, maintained, or extended dosing intervals
Latest:
EyeCon 2024: Key takeaways for enhanced patient care from Day 1Optometry cochairs Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, MA, FAAO, highlight the conference’s focus on collaboration, featuring topics like red flags for patient care, thyroid eye disease, and diabetes management.
Latest:
Driving practice growth: Expand on link between dry eye, aestheticsOne obvious trend has been that dry eye disease is a concurrent problem for virtually all my patients, and we need to address it for optimum comfort and surgical results.
Latest:
Ocular surface health and IOL choicesEnhanced monofocal technology may benefit patients with cataracts and dry eye.
